Patents by Inventor Yutaka Kohgo
Yutaka Kohgo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11752180Abstract: The present invention provides an intestinal tract protective agent comprising a polyphosphoric acid or a pharmaceutically acceptable salt thereof as an active ingredient.Type: GrantFiled: August 6, 2020Date of Patent: September 12, 2023Assignees: National University Corporation Asahikawa Medical University, Sapporo Holdings LimitedInventors: Yutaka Kohgo, Mikihiro Fujiya, Nobuhiro Ueno, Syuichi Segawa, Naoyuki Kobayashi
-
Publication number: 20200368299Abstract: The present invention provides an intestinal tract protective agent comprising a polyphosphoric acid or a pharmaceutically acceptable salt thereof as an active ingredient.Type: ApplicationFiled: August 6, 2020Publication date: November 26, 2020Applicants: National University Corporation Asahikawa Medical University, Sapporo Holdings LimitedInventors: Yutaka Kohgo, Mikihiro Fujiya, Nobuhiro Ueno, Syuichi Segawa, Naoyuki Kobayashi
-
Patent number: 10792315Abstract: The present invention provides an intestinal tract protective agent comprising a polyphosphoric acid or a pharmaceutically acceptable salt thereof as an active ingredient.Type: GrantFiled: March 28, 2011Date of Patent: October 6, 2020Assignees: National University Corporation Asahikawa Medical University, Sapporo Holdings LimitedInventors: Yutaka Kohgo, Mikihiro Fujiya, Nobuhiro Ueno, Syuichi Segawa, Naoyuki Kobayashi
-
Patent number: 9796605Abstract: Disclosed is a water-insoluble polymeric iron chelating agent having a polymer backbone and an aromatic ring attached to the polymer backbone through an —NH—CH2— bond, wherein the aromatic ring has one or two first functional groups in the form of hydroxyl group and one or two second functional groups located at the ortho position with respect to the first functional group; and wherein the second functional group is —OH, —COOH, or a group represented by formula (I) wherein A represents —CH3, —CH2—CH3, —CH2—C6H5, —CH2—C5H4N or —CH2—COOH and B represents —CH2—COOH. The water-insoluble polymeric iron chelating agent of the present invention offers the advantages of being capable of selectively chelating iron ions, particularly biologically unstable iron, and being insoluble in water, and moreover not being incorporated in metabolic processes in vivo.Type: GrantFiled: January 12, 2012Date of Patent: October 24, 2017Assignees: DISEASE ADSORPTION SYSTEM TECHNOLOGIES CO., LTD., NATIONAL UNIVERSITY CORPORATION ASAHIKAWA MEDICAL UNIVERSITYInventors: Yuzo Nishida, Yutaka Kohgo, Katsuya Ikuta, Katsunori Sasaki
-
Patent number: 8951795Abstract: The present invention relates to a method of safely and simply inducing differentiation of mononuclear cells into cells that promote neovascular stabilization and maturation, and lead to recovering from ischemia or tissue repair. The cells according to the present invention are obtained by inducing differentiation of a mononuclear cell by culturing the mononuclear cell in a medium (particularly a serum-free medium) containing one or more selected from vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), thrombopoietin (TPO), granulocyte-colony stimulating factor (G-CSF) and FMS-like tyrosine kinase 3 ligand (FLT3L), and collecting a cell population expressing CD11b.Type: GrantFiled: March 29, 2010Date of Patent: February 10, 2015Assignee: National University Corporation Asahikawa Medical UniversityInventors: Yusuke Mizukami, Junpei Sasajima, Yoshiaki Sugiyama, Kazuya Sato, Yutaka Kohgo
-
Patent number: 8623661Abstract: The present invention provides an iron chelating agent which can selectively chelate iron ions. The iron chelating agent of the present invention includes a compound represented by the following formula (1) or a salt thereof (wherein, ring Z represents an aromatic hydrocarbon ring or an aromatic heterocyclic ring; R1 represents an alkylene group; R2 and R3 each independently represent a hydrogen atom, a hydrocarbon group or a group having chelating ability; and the total coordination number of the groups represented by R2 and R3 is 1 or 2.Type: GrantFiled: September 18, 2009Date of Patent: January 7, 2014Assignees: National University Corporation Asahikawa Medical College, Yamagata UniversityInventors: Yutaka Kohgo, Katsuya Ikuta, Katsunori Sasaki, Yuzo Nishida
-
Publication number: 20130292337Abstract: Disclosed is a water-insoluble polymeric iron chelating agent having a polymer backbone and an aromatic ring attached to the polymer backbone through an —NH—CH2— bond, wherein the aromatic ring has one or two first functional groups in the form of hydroxyl group and one or two second functional groups located at the ortho position with respect to the first functional group; and wherein the second functional group is —OH, —COOH, or a group represented by formula (I) wherein A represents —CH3, —CH2—CH3, —CH2—C6H5, —CH2—C5H4N or —CH2—COOH and B represents —CH2—COOH. The water-insoluble polymeric iron chelating agent of the present invention offers the advantages of being capable of selectively chelating iron ions, particularly biologically unstable iron, and being insoluble in water, and moreover not being incorporated in metabolic processes in vivo.Type: ApplicationFiled: January 12, 2012Publication date: November 7, 2013Applicants: National University Corporation ASAHIKAWA MEDICAL UNIVERSITY, DISEASE ADSORPTION SYSTEM TECHNOLOGIES CO., LTD.Inventors: Yuzo Nishida, Yutaka Kohgo, Katsuya Ikuta, Katsunori Sasaki
-
Patent number: 8491887Abstract: An anticancer therapy using autologous cells or the like, which induces the regression of cancer or has favorable drug delivery effects and brings about reduction or withdrawal of a hypoxic region(s) in tumor is provided. Transplantation of endothelial progenitor cells, via intravenously or other methods leads to tumor growth inhibition, an increase of the vascular density with an enlargement of the vascular diameter, and reduction of a hypoxic region(s) in the tumor. Allogeneic transplantation of endothelial progenitor cells may be achieved to secure the cells for the therapy, however, autologous transplantation of endothelial progenitor cells from cancer patients would be desirable to evade rejection. When autologous cells are used, mononuclear cells are separated from the peripheral blood or bone marrow of the patient and cultured using an endothelial differentiation medium containing cytokines such as VEGF to obtain adherent cells, which can then be collected and used as endothelial progenitor cells.Type: GrantFiled: May 19, 2008Date of Patent: July 23, 2013Assignee: National University Corporation Asahikawa Medical UniversityInventors: Yusuke Mizukami, Yutaka Kohgo, Kazumasa Nakamura
-
Publication number: 20130171118Abstract: The present invention provides an intestinal tract protective agent comprising a polyphosphoric acid or a pharmaceutically acceptable salt thereof as an active ingredient.Type: ApplicationFiled: March 28, 2011Publication date: July 4, 2013Applicants: SAPPORO BREWERIES LIMITED, National University Corporation ASAHIKAWA MEDICAL UNIVERSITYInventors: Yutaka Kohgo, Mikihiro Fujiya, Nobuhiro Ueno, Syuichi Segawa, Naoyuki Kobayashi
-
Publication number: 20120100610Abstract: The present invention relates to a method of safely and simply inducing differentiation of mononuclear cells into cells that promote neovascular stabilization and maturation, and lead to recovering from ischemia or tissue repair. The cells according to the present invention are obtained by inducing differentiation of a mononuclear cell by culturing the mononuclear cell in a medium (particularly a serum-free medium) containing one or more selected from vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), thrombopoietin (TPO), granulocyte-colony stimulating factor (G-CSF) and FMS-like tyrosine kinase 3 ligand (FLT3L), and collecting a cell population expressing CD11b.Type: ApplicationFiled: March 29, 2010Publication date: April 26, 2012Applicant: National University Corporation Asahikawa MedicalInventors: Yusuke Mizukami, Junpei Sasajima, Yoshiaki Sugiyama, Kazuya Sato, Yutaka Kohgo
-
Publication number: 20100143311Abstract: It is intended to provide anticancer therapy using autologous cells or the like, which induces the regression of cancer or has favorable drug delivery effects and brings about reduction or withdrawal of a hypoxic region(s) in tumor. Transplantation of endothelial progenitor cells, via intravenously or other methods leads to tumor growth inhibition, an increase of the vascular density with an enlargement of the vascular diameter, and reduction of a hypoxic region(s) in the tumor. Allogeneic transplantation of endothelial progenitor cells may be achieved to secure the cells for the therapy, however, autologous transplantation of endothelial progenitor cells from cancer patients would be desirable in order to evade rejection.Type: ApplicationFiled: May 19, 2008Publication date: June 10, 2010Applicant: NATIONAL UNIVERSITY CORPORATION ASAHIKAWA MEDICALInventors: Yusuke Mizukami, Yutaka Kohgo, Kazumasa Nakamura
-
Patent number: 5843677Abstract: The present invention is directed to a method of immunoassay of asialoglycoprotein receptors (AGPR) by bringing a specimen into contact with a monoclonal antibody that recognizes AGPR, wherein the pH of a diluted specimen solution is adjusted from 5 to 7 or phenol is added to a solution of an enzyme-labeled antibody. This method is excellent in the sensitivity and accuracy of AGPR assay and can be applied also to the screening of hepatopathy remedies.Type: GrantFiled: October 18, 1996Date of Patent: December 1, 1998Assignee: Daiichi Pure Chemicals Co., Ltd.Inventors: Yoshiro Niitsu, Yutaka Kohgo, Junji Kato, Hirokazu Yago, Hisashi Hanada, Koji Ushizawa